Navigation Links
ShangPharma Announces Second Quarter 2011 Results
Date:8/22/2011

ories as well as major multinational biotech and pharmaceutical companies' Chinese R&D centers.  In light of the Chinese government's rising support of locally-developed drugs and more R&D investment into China by global pharmaceutical and biotech companies, the Company anticipates its China business will continue to grow and become a larger percentage of total revenues.

Revenue from the Company's top-10 customers increased by 24.4% compared with the same period last year, and accounted for 61.8% of the total revenue compared with 62.6% in the same quarter last year.  The increase in top-10 customers' revenue has further demonstrated our continued efforts and commitments to become preferred business partners with global leading pharmaceutical and biotech companies.  In addition, percentage of revenue from top-10 customers as of total revenue has continued to decrease due to the very strong increase in revenue contribution from China-based clients and increased diversification of the customer base.

Net revenues from full-time-equivalent ("FTE")-based services were $19.7 million, an increase of 26.5% from $15.6 million in the second quarter of 2010, primarily due to an increase in FTE numbers and higher FTE rates.

Net revenues from fee-for-service-based services were $7.8 million, an increase of 24.9% from $6.2 million in the second quarter of 2010.  The rise was primarily driven by the Company's service offerings including discovery biology, preclinical development and newer biologics services. The growth in fee-for-service-based revenues reflects the Company's ability to cross-sell more services to existing customers as well as strong demand from new customers.  The Company also saw strong demand from customers that use multiple services.

Gross profit was $9.1 million, an increase of 23.6% from $7.4 million in the second quarter of 2010, primarily due to the increase in revenues, operational efficie
'/>"/>

SOURCE ShangPharma Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16

Related biology technology :

1. ShangPharma Corporation Named a Top Ten Chinese Outsourcing Enterprise
2. ShangPharma Announces First Quarter 2011 Results
3. ShangPharma Corp. to Announce Fourth Quarter and Full Year 2010 Financial Results on March 15, 2011
4. Stem Cell Assurance, Inc. Announces Change of Name to BioRestorative Therapies, Inc.
5. Syndax Pharmaceuticals Announces Issuance of EU Patent for Entinostat
6. Regeneron Announces Review of Biologics License Application for EYLEA™ (aflibercept injection) Extended by Three Months by FDA
7. ACMG Announces New Online Live Learning Center: Will Bring Genetics and Genomics Education to Varied Health Professionals
8. Neurologix Announces Second Quarter 2011 Financial Results
9. Bion Announces New U.S. Patent for Phosphorus Removal
10. ViaCyte Announces Executive Management Changes
11. NeoStem Announces the Receipt of Over $1,700,000 in DOD Funding for its VSEL™ Technology Being Developed to Treat Osteoporosis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/3/2015)... ... August 03, 2015 , ... ... pumps to its comprehensive line of analytical laboratory equipment. With optimized features, such ... pumps provide a chemically resistant and maintenance-free solution for a broad range of ...
(Date:7/31/2015)... ... July 31, 2015 , ... ... and quantification of partially hydrolyzed gluten in foods, has been accepted by AOAC ... method “Partially Hydrolyzed Gluten in Fermented Cereal-Based Products by R5 Competitive ELISA,” based ...
(Date:7/30/2015)... Grenoble, France and Dallas, TX, USA (PRWEB) , ... ... ... manufacturer of innovative nano and microsystems, has appointed Francois Vieillard as Sales & ... & Marketing at executive positions, Francois Vieillard will be responsible for reinforcing Tronics’ ...
(Date:7/30/2015)... Kan. , July 30, 2015   ... a pet therapeutics company focused on the licensing, ... companion animals, today announced that its strategic partner ... a dose confirmation study of AT-016, an adipose-derived ... for the treatment of osteoarthritis pain in dogs. ...
Breaking Biology Technology:Sterlitech Launches New Line of Vacuum Pumps 2RIDASCREEN® Competitve Gliadin Receives AOAC Official First Action Status 2Tronics appoints Francois Vieillard as Sales and Marketing Director 2Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 2Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 3Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 4Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 5
... In the smooth, white, bunny-suited clean-room world of silicon wafers ... may go a long way, perhaps all the way to ... Their research shows that light ricocheting around inside the ... film is ultra thin. A film that,s nanoscale-thin and has ...
... Decision Resources, one of the world,s leading research and ... owing to increasing generic availability of antihypertensive agents, the ... 2009 to $23 billion in 2019 in the United ... The Pharmacor 2010 findings from the topic ...
... Enters into Share Transfer Agreement -- SHENZHEN, China, Sept. 28 /PRNewswire-Asia-FirstCall/ -- ... ... lpUnit=,PRN,; --> ... = function(data) { var s = ,; var first_result; // Results are keyed by longUrl, so ...
Cached Biology Technology:Solar cells thinner than wavelengths of light hold huge power potential 2Solar cells thinner than wavelengths of light hold huge power potential 3Due to Generic Erosion, the Hypertension Drug Market Will Decline by $3 Billion from 2009 to 2019 2Tongjitang Chinese Medicines Company Enters into Share Transfer Agreement 2Tongjitang Chinese Medicines Company Enters into Share Transfer Agreement 3Tongjitang Chinese Medicines Company Enters into Share Transfer Agreement 4Tongjitang Chinese Medicines Company Enters into Share Transfer Agreement 5Tongjitang Chinese Medicines Company Enters into Share Transfer Agreement 6Tongjitang Chinese Medicines Company Enters into Share Transfer Agreement 7Tongjitang Chinese Medicines Company Enters into Share Transfer Agreement 8
(Date:7/13/2015)... Jul. 13, 2015 NXT-ID, Inc. (NASDAQ: ... authentication company focused on the growing mobile commerce ... patent 62/188684 for BEHAVIORAL-DIRECTED AUTHENTIATION METHOD ... convenient and secure method to make payments.  With ... methods, introduced with its groundbreaking voice-direct payment patent ...
(Date:7/9/2015)... PLEASANTON, Calif. , July 9, 2015 /PRNewswire/ ... tools, today announcing its acquisition of Avid Nano. ... dynamic light scattering (DLS) systems.    ... world,s smallest, fastest and easiest to use protein ... system that measures a protein,s hydrodynamic size, size ...
(Date:7/8/2015)... , N.J. and NEW YORK , July ... Guidepoint today announced BD & Guidepoint ... companies with free access to Guidepoint,s expert network services. ... that are developing cutting-edge technologies to improve healthcare delivery ... Guidepoint research manager, each start-up entrepreneur will be able ...
Breaking Biology News(10 mins):NXT-ID Patents Behavior-Directed Payments 2NXT-ID Patents Behavior-Directed Payments 3NXT-ID Patents Behavior-Directed Payments 4Unchained Labs just can't get enough, acquires Avid Nano, rocks out the new pUNk! 2BD and Guidepoint Team to Connect Healthcare Start-up Companies With Business and Scientific Experts 2BD and Guidepoint Team to Connect Healthcare Start-up Companies With Business and Scientific Experts 3
... 2003 epidemic of Highly Pathogenic Avian Influenza (HPAI) in ... in the developed world. Gert-Jan Boender and colleagues have ... model which can predict the probability of infection from ... identify high-risk areas in the Netherlands and analyze various ...
... more bacteria are antibiotic resistant and because antibiotics are ... to developing new antibacterial strategies, taken by researchers from ... amount of iron (Fe), which is critical for bacterial ... study, which appears online on March 15 in advance ...
... Pennsylvania School of Medicine have discovered that an enzyme ... that is defective in cystic fibrosis patients. The disruption ... to airways causes thick mucus to buildup inside the ... treating lung infections in some cystic fibrosis (CF) patients. ...
Cached Biology News:Penn study on lung-infecting bacterial enzyme suggests new approach to cystic fibrosis treatment 2
4-Hydroxy-3-nitrophenylacetyl hapten is conjugated to SGG (Sheep gamma globulin) lysine through amide bonds. This product is homologous to NP-BSA....
MOUSE ANTI HUMAN B-CELLS (FMC7):FITC Immunogen: HRIK cells - Human B-Lymphoblastoid line...
... Fiberboard boxes are ideal for use in refrigerators, freezers, ... racks. Four vibrant colors allow for color coding to ... liquid nitrogen drainage or promote cool air circulation. Supplied ... holds 81 tubes. Box dimensions: 13 x ...
RABBIT ANTI PARATHION...
Biology Products: